Evoke Pharma Draws Complete Response Letter for Diabetic Treatment

Drug Industry Daily
A A
The FDA issued a complete response letter to Evoke Pharma for its Gimoti (metoclopramide) nasal spray for treatment of diabetic gastroparesis, a condition that delays emptying of the stomach.

To View This Article:

Login

Subscribe To Drug Industry Daily